Your browser doesn't support javascript.
loading
Application of an NMR/Crystallography Fragment Screening Platform for the Assessment and Rapid Discovery of New HIV-CA Binding Fragments.
Lang, Stuart; Fletcher, Daniel A; Petit, Alain-Pierre; Luise, Nicola; Fyfe, Paul; Zuccotto, Fabio; Porter, David; Hope, Anthony; Bellany, Fiona; Kerr, Catrina; Mackenzie, Claire J; Wyatt, Paul G; Gray, David W.
Afiliação
  • Lang S; Cresset Discovery, New Cambridge House, Bassingbourn Road, Litlington, Cambridgeshire, SG80SSS.
  • Fletcher DA; BioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH.
  • Petit AP; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Luise N; Alira Health, Av. De Josep Tarradellas, 123, 7th Floor, 08029, Barcelona, Spain.
  • Fyfe P; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Zuccotto F; Vertex Pharmaceuticals (Europe) Ltd, 86-88, Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RW.
  • Porter D; Evotec (UK) Ltd, Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ.
  • Hope A; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Bellany F; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Kerr C; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Mackenzie CJ; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Wyatt PG; Sitala Bio Ltd, Unit D6, Grain House Mill Court, Great Shelford, Cambridge, CB22 5LD.
  • Gray DW; Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
ChemMedChem ; 19(13): e202400025, 2024 Jul 02.
Article em En | MEDLINE | ID: mdl-38581280
ABSTRACT
Identification and assessment of novel targets is essential to combat drug resistance in the treatment of HIV/AIDS. HIV Capsid (HIV-CA), the protein playing a major role in both the early and late stages of the viral life cycle, has emerged as an important target. We have applied an NMR fragment screening platform and identified molecules that bind to the N-terminal domain (NTD) of HIV-CA at a site close to the interface with the C-terminal domain (CTD). Using X-ray crystallography, we have been able to obtain crystal structures to identify the binding mode of these compounds. This allowed for rapid progression of the initial, weak binding, fragment starting points to compounds 37 and 38, which have 19F-pKi values of 5.3 and 5.4 respectively.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Anti-HIV Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Anti-HIV Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article